{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Active+capsule&page=22",
    "query": {
      "intervention": "Active capsule",
      "page": 22
    },
    "page_size": 10
  },
  "pagination": {
    "page": 22,
    "page_size": 10,
    "total_count": 1413,
    "total_pages": 142,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Active+capsule&page=23&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Active+capsule&page=21&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-25T04:20:58.023Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03289832",
      "title": "Effect of Orally Delivered Phytochemicals on Aging and Inflammation in the Skin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Healthy Adults"
      ],
      "interventions": [
        {
          "name": "Crucera-SGS",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Meriva 500-SF",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 25,
      "start_date": "2017-09-25",
      "completion_date": "2019-10-23",
      "has_results": false,
      "last_update_posted_date": "2020-07-21",
      "last_synced_at": "2026-10-25T04:20:58.023Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03289832"
    },
    {
      "nct_id": "NCT03926611",
      "title": "This Was a Dose-finding Study to Evaluate Efficacy and Safety of LOU064 in Patients With CSU Inadequately Controlled by H1-antihistamines",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Spontaneous Urticaria"
      ],
      "interventions": [
        {
          "name": "LOU064 Arm 1",
          "type": "DRUG"
        },
        {
          "name": "LOU064 Arm 2",
          "type": "DRUG"
        },
        {
          "name": "LOU064 Arm 3",
          "type": "DRUG"
        },
        {
          "name": "LOU064 Arm 4",
          "type": "DRUG"
        },
        {
          "name": "LOU064 Arm 5",
          "type": "DRUG"
        },
        {
          "name": "LOU064 Arm 6",
          "type": "DRUG"
        },
        {
          "name": "Placebo arm",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 311,
      "start_date": "2019-06-06",
      "completion_date": "2021-04-15",
      "has_results": true,
      "last_update_posted_date": "2022-04-29",
      "last_synced_at": "2026-10-25T04:20:58.023Z",
      "location_count": 11,
      "location_summary": "Litchfield Park, Arizona • Little Rock, Arkansas • Mission Viejo, California + 8 more",
      "locations": [
        {
          "city": "Litchfield Park",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Mission Viejo",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03926611"
    },
    {
      "nct_id": "NCT03013998",
      "title": "Study of Biomarker-Based Treatment of Acute Myeloid Leukemia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Previously Untreated Relapsed Refractory Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Samalizumab (BAML-16-001-S1)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BI 836858 (BAML-16-001-S2)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Daunorubicin (BAML-16-001-S1)",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine (BAML-16-001-S1)",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine (BAML-16-001-S2)",
          "type": "DRUG"
        },
        {
          "name": "AG-221 (BAML-16-001-S3)",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine (BAML-16-001-S3)",
          "type": "DRUG"
        },
        {
          "name": "Entospletinib (BAML-16-001-S4)",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine (BAML-16-001-S4)",
          "type": "DRUG"
        },
        {
          "name": "Entospletinib (BAML-16-001-S5)",
          "type": "DRUG"
        },
        {
          "name": "Decitabine (BAML-16-001-S5)",
          "type": "DRUG"
        },
        {
          "name": "Entospletinib (BAML-16-001-S6)",
          "type": "DRUG"
        },
        {
          "name": "Daunorubicin (BAML-16-001-S6)",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine (BAML-16-001-S6)",
          "type": "DRUG"
        },
        {
          "name": "Pevonedistat (BAML-16-001-S9)",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine (BAML-16-001-S9)",
          "type": "DRUG"
        },
        {
          "name": "AG-120 (BAML-16-001-S16)",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine (BAML-16-001-S16)",
          "type": "DRUG"
        },
        {
          "name": "Gilteritinib (BAML-16-001-S8 Group 1)",
          "type": "DRUG"
        },
        {
          "name": "Decitabine (BAML-16-001-S8 Group 1)",
          "type": "DRUG"
        },
        {
          "name": "AZD5153 (BAML-16-001-S10)",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax (BAML-16-001-S10)",
          "type": "DRUG"
        },
        {
          "name": "TP-0903 (BAML-16-001-S14)",
          "type": "DRUG"
        },
        {
          "name": "Decitabine (BAML-16-001-S14)",
          "type": "DRUG"
        },
        {
          "name": "Decitabine (BAML-16-001-S8 Group 2)",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax (BAML-16-001-S8 Group 2)",
          "type": "DRUG"
        },
        {
          "name": "AZD5991 (BAML-16-001-S18)",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine (BAML-16-001-S18)",
          "type": "DRUG"
        },
        {
          "name": "SNDX-5613 (BAML-16-001-S17)",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine (BAML-16-001-S17)",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax (BAML-16-001-S17)",
          "type": "DRUG"
        },
        {
          "name": "Gilteritinib (BAML-16-001-S8 Group 2)",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax (BAML-16-001-S12 Arm A)",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine (BAML-16-001-S12 Arm A)",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax (BAML-16-001-S12 Arm B)",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine (BAML-16-001-S12 Arm B)",
          "type": "DRUG"
        },
        {
          "name": "ZE46-0134 (BAML-16-001-S21 Group 1)",
          "type": "DRUG"
        },
        {
          "name": "ficlatuzumab (BAML-16-001-S24)",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine (BAML-16-001-S24)",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax (BAML-16-001-S24)",
          "type": "DRUG"
        },
        {
          "name": "ZE46-0134 (BAML-16-001-S21 Group 2)",
          "type": "DRUG"
        },
        {
          "name": "Bleximenib (BAML-16-001-S25/HO181)",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine (BAML-16-001-S25/HO181)",
          "type": "DRUG"
        },
        {
          "name": "Daunorubicin or Idarubicin (BAML-16-001-S25/HO181)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (BAML-16-001-S25/HO181)",
          "type": "DRUG"
        },
        {
          "name": "Revumenib (BAML-16-001-S26/HO177)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (BAML-16-001-S26/HO177)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Beat AML, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3000,
      "start_date": "2016-11",
      "completion_date": "2032-12",
      "has_results": false,
      "last_update_posted_date": "2026-09-03",
      "last_synced_at": "2026-10-25T04:20:58.023Z",
      "location_count": 31,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03013998"
    },
    {
      "nct_id": "NCT04965272",
      "title": "A Study To Assess Adverse Events and Change in Disease Activity With Oral Cariprazine When Added to Antidepressant Therapies (ADTs) Compared to Placebo in Adult Participants With Generalized Anxiety Disorder (GAD) Who Have Had an Inadequate Response to ADTs Alone",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Generalized Anxiety Disorder"
      ],
      "interventions": [
        {
          "name": "Cariprazine 0.75 mg/day",
          "type": "DRUG"
        },
        {
          "name": "Cariprazine 1.5 mg/day",
          "type": "DRUG"
        },
        {
          "name": "Cariprazine 3.0 mg/day",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 0,
      "start_date": "2021-08-18",
      "completion_date": "2021-08-24",
      "has_results": false,
      "last_update_posted_date": "2022-04-12",
      "last_synced_at": "2026-10-25T04:20:58.023Z",
      "location_count": 36,
      "location_summary": "Little Rock, Arkansas • Colton, California • Costa Mesa, California + 29 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Colton",
          "state": "California"
        },
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Culver City",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04965272"
    },
    {
      "nct_id": "NCT00960622",
      "title": "Switch From Combivir or Trizivir to Truvada - Mitochondrial Effects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HIV"
      ],
      "interventions": [
        {
          "name": "Truvada",
          "type": "DRUG"
        },
        {
          "name": "Combivir",
          "type": "DRUG"
        },
        {
          "name": "Trizivir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "St. Luke's-Roosevelt Hospital Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2006-08",
      "completion_date": "2009-07",
      "has_results": true,
      "last_update_posted_date": "2013-03-04",
      "last_synced_at": "2026-10-25T04:20:58.023Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00960622"
    },
    {
      "nct_id": "NCT01507753",
      "title": "Omega-3 and Therapy Study for Childhood Bipolar Disorder- Not Otherwise Specified",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Bipolar Disorder"
      ],
      "interventions": [
        {
          "name": "Omega-3 Supplementation",
          "type": "DRUG"
        },
        {
          "name": "Psychoeducational Psychotherapy (PEP)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "L. Eugene Arnold",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "14 Years",
        "sex": "ALL",
        "summary": "7 Years to 14 Years"
      },
      "enrollment_count": 23,
      "start_date": "2011-09",
      "completion_date": "2014-09",
      "has_results": false,
      "last_update_posted_date": "2016-03-08",
      "last_synced_at": "2026-10-25T04:20:58.023Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01507753"
    },
    {
      "nct_id": "NCT06460181",
      "title": "Impact of Astaxanthin on Cognition in Recreationally Active Females",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Mental Fatigue"
      ],
      "interventions": [
        {
          "name": "Astaxanthin",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "University of North Alabama",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "39 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 39 Years · Female only"
      },
      "enrollment_count": 26,
      "start_date": "2024-08-01",
      "completion_date": "2024-12-14",
      "has_results": true,
      "last_update_posted_date": "2026-05-26",
      "last_synced_at": "2026-10-25T04:20:58.023Z",
      "location_count": 1,
      "location_summary": "Florence, Alabama",
      "locations": [
        {
          "city": "Florence",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06460181"
    },
    {
      "nct_id": "NCT06385795",
      "title": "A Study of NOE-115 in Women With Vasomotor Symptoms Due to Menopause",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Menopause Syndrome",
        "Menopause",
        "Hot Flashes"
      ],
      "interventions": [
        {
          "name": "NOE-115",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Noema Pharma AG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "60 Years",
        "sex": "FEMALE",
        "summary": "45 Years to 60 Years · Female only"
      },
      "enrollment_count": 40,
      "start_date": "2024-04-22",
      "completion_date": "2025-08-13",
      "has_results": false,
      "last_update_posted_date": "2025-09-12",
      "last_synced_at": "2026-10-25T04:20:58.023Z",
      "location_count": 5,
      "location_summary": "San Diego, California • Jacksonville, Florida • Atlanta, Georgia + 2 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06385795"
    },
    {
      "nct_id": "NCT06306157",
      "title": "Low Dose Naltrexone Therapy for Complex Regional Pain Syndrome",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Complex Regional Pain Syndrome",
        "Chronic Pain",
        "Causalgia",
        "Complex Regional Pain Syndrome Type I",
        "Complex Regional Pain Syndrome Type II"
      ],
      "interventions": [
        {
          "name": "Low dose naltrexone",
          "type": "DRUG"
        },
        {
          "name": "Placebo sugar capsules",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hospital for Special Surgery, New York",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 40,
      "start_date": "2024-01-02",
      "completion_date": "2026-11",
      "has_results": false,
      "last_update_posted_date": "2026-06-18",
      "last_synced_at": "2026-10-25T04:20:58.023Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06306157"
    },
    {
      "nct_id": "NCT00959751",
      "title": "Study of the Safety and Effectiveness of NXN-188 for the Treatment of Migraine Headache Without Aura",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Migraine Without Aura"
      ],
      "interventions": [
        {
          "name": "NXN-188",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NeurAxon Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 195,
      "start_date": "2009-07",
      "completion_date": "2010-03",
      "has_results": true,
      "last_update_posted_date": "2014-07-23",
      "last_synced_at": "2026-10-25T04:20:58.023Z",
      "location_count": 4,
      "location_summary": "St. Petersburg, Florida • Atlanta, Georgia • Mount Vernon, New York + 1 more",
      "locations": [
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Mount Vernon",
          "state": "New York"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00959751"
    }
  ]
}